CHRO Stock Overview
A clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Channel Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.66 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$0.45 |
| Beta | 0 |
| 11 Month Change | -1.49% |
| 3 Month Change | -24.14% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHRO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.6% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how CHRO performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CHRO performed against the US Market.
Price Volatility
| CHRO volatility | |
|---|---|
| CHRO Average Weekly Movement | 20.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CHRO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CHRO's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 6 | Frank Knuettel | www.chromocell.com |
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
Channel Therapeutics Corporation Fundamentals Summary
| CHRO fundamental statistics | |
|---|---|
| Market cap | US$3.98m |
| Earnings (TTM) | -US$10.07m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs CHRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHRO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$2.58m |
| Gross Profit | -US$2.58m |
| Other Expenses | US$7.49m |
| Earnings | -US$10.07m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -160.3% |
How did CHRO perform over the long term?
See historical performance and comparison